The closest thing to a COVID ‘cure’? Eli Lilly’s combination antibody drug cuts the risk of COVID-19 hospitalization and death by 87%, study finds
Eli Lilly & Co says its combination antibody therapy is effective at treating mild to moderate cases of COVID-19. The treatment, a mixture of drugs bamlanivimab and etesevimab, was developed by Indianapolis-based Lilly and the Canadian company AbCellera. It recognizes the virus once a person is infected and attaches to it, preventing the pathogen from entering human …